Join the Arexvy group to help and get support from people like you.
Arexvy News (Page 2)
RSV Burden Remains High in Young Children in the United States
WEDNESDAY, Dec. 11, 2024 – The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA...
COVID-19, Flu, RSV Vaccine Coverage Low for Nursing Home Residents
TUESDAY, Nov. 26, 2024 – COVID-19, influenza, and respiratory syncytial virus (RSV) vaccination coverage is low among nursing home residents early in the 2024 to 2025 season, according to research...
Study Assesses Risk for 28-Day Hospitalization for Adults With RSV
WEDNESDAY, Nov. 20, 2024 – A number of adults with outpatient medically attended respiratory syncytial virus (MA-RSV) infection experience hospitalization within 28 days, with a higher proportion...
Optimal Timing of Maternal RSV Vaccine Determined to Be at Least Five Weeks Before Delivery
THURSDAY, Nov. 21, 2024 – Respiratory syncytial virus (RSV) vaccination at least five weeks prior to delivery results in the highest transplacental transfer of maternal antibodies to the neonate,...
RSV Hospitalizations Linked to Considerable Burden in Adults
FRIDAY, Nov. 15, 2024 – Respiratory syncytial virus (RSV) is associated with a considerable burden of hospitalizations, intensive care unit (ICU) admissions, and in-hospital deaths among adults,...
RSV Vaccination Prevents Associated Hospitalization, Emergency Encounters
THURSDAY, Nov. 7, 2024 – For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters,...
Real-World Study Confirms RSV Vaccine's, Arexvy and Abrysvo, Protective Power for Seniors
FRIDAY, Oct. 18, 2024 – A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or...
IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
FRIDAY, Oct. 18, 2024 – Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV) is less likely with an increasing social...
Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
WEDNESDAY, Oct. 16, 2024 – Public concerns about contracting RSV (respiratory syncytial virus) have significantly declined during the past year, a new survey shows. About 1 in 4 people (26%) are now...
FDA Approves Expanded Age Indication for GSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
Philadelphia, PA June 07 2024 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for...
FDA Approves Arexvy (respiratory syncytial virus vaccine, adjuvanted) Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
May 3, 2023 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower...